An open-label phase 2 multicohort study (NCT04225117) is currently ongoing and enrolling into 6 tumor-specific cohorts, among those hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+ /HER2-) and triple-negative breast cancer, squamous non-small cell lung cancer, non-squamous non-small cell lung cancer, head and neck cancer, and gastric/esophageal adenocarcinoma and squamous cell carcinoma. Here, ERBB2 is linked to squamous cell carcinoma.